NO20070914L - Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander - Google Patents

Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander

Info

Publication number
NO20070914L
NO20070914L NO20070914A NO20070914A NO20070914L NO 20070914 L NO20070914 L NO 20070914L NO 20070914 A NO20070914 A NO 20070914A NO 20070914 A NO20070914 A NO 20070914A NO 20070914 L NO20070914 L NO 20070914L
Authority
NO
Norway
Prior art keywords
conditions
methods
nervous system
system disorders
treating nervous
Prior art date
Application number
NO20070914A
Other languages
English (en)
Inventor
Darlene Coleman Deecher
Magid A Abou-Gharbia
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20070914L publication Critical patent/NO20070914L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår selektive dopamin-gjenopptaksinhibitorer, innbefattende (-)-1-(3,4-diklorfenyl)-3-azabisyklo[3.1.0]heksan, (-)-1-(4-metylfenyl)-3-azabisyklo[3.1.0]heksan, mazindol, metylfenidat og 1-(2-[bis(4-fluorfenyl)metoksy]etyl)-4-(3-fenylpropyl)piperazin, og metoder for anvendelse av dem for behandling av visse nervesystemforstyrrelser og -tilstander, innbefattende blant annet vasomotoriske symptomer (VMS), kronisk smerte og Shy-Dragersyndromet.
NO20070914A 2004-07-22 2007-02-16 Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander NO20070914L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59010304P 2004-07-22 2004-07-22
US59020304P 2004-07-22 2004-07-22
PCT/US2005/025977 WO2006012476A2 (en) 2004-07-22 2005-07-21 Method for treating nervous system disorders and conditions

Publications (1)

Publication Number Publication Date
NO20070914L true NO20070914L (no) 2007-04-20

Family

ID=35241037

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070914A NO20070914L (no) 2004-07-22 2007-02-16 Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander

Country Status (12)

Country Link
US (2) US20060019966A1 (no)
EP (1) EP1773321A2 (no)
JP (1) JP2008507551A (no)
KR (1) KR20070045278A (no)
AU (1) AU2005266996A1 (no)
BR (1) BRPI0513711A (no)
CA (1) CA2574315A1 (no)
IL (1) IL180732A0 (no)
MX (1) MX2007000848A (no)
NO (1) NO20070914L (no)
RU (1) RU2007102290A (no)
WO (1) WO2006012476A2 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
MX2007000851A (es) * 2004-07-22 2007-03-26 Wyeth Corp Procedimiento para el tratamiento de trastornos y dolencias del sistema nervioso.
CA2574310A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
US20070021488A1 (en) * 2005-07-21 2007-01-25 Wyeth Method for treating nervous system disorders and conditions
FR2899476B1 (fr) * 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
US20090076079A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched methylphenidate
US9339500B2 (en) * 2008-03-04 2016-05-17 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods
US20150367180A1 (en) * 2014-06-18 2015-12-24 Acushnet Company Low compression golf ball

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3166571A (en) * 1962-06-06 1965-01-19 American Cyanamid Co 1-phenyl-1, 2-cyclopropane dicarboximides
US3344026A (en) * 1966-05-16 1967-09-26 American Cyanamid Co Dosage unit composition of 1-(p-chlorophenyl)-1, 2-cyclopropanedicarboximide for relief of depression
US3892772A (en) * 1973-12-04 1975-07-01 American Cyanamid Co Isomer of 1-(p-chlorophenyl)-1,2-cyclopropanedicarboximide and method of use
US4088652A (en) * 1975-07-31 1978-05-09 American Cyanamid Company Acylazabicyclohexanes
US4131611A (en) * 1975-07-31 1978-12-26 American Cyanamid Company Azabicyclohexanes
US4118393A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Phenyl azabicyclohexanones
US4118417A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids
US4435419A (en) * 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
DE3378208D1 (en) * 1982-12-21 1988-11-17 Ciba Geigy Ag Substituted azabicycloalkanes, their use, pharmaceutical preparations containing these compounds and process for preparing these compounds
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
DE19919336A1 (de) * 1999-04-27 2000-11-16 Consortium Elektrochem Ind Verfahren zur Ringspaltung von Thiazolidinderivaten
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
ATE369330T1 (de) * 2001-02-12 2007-08-15 Wyeth Corp O-desmethyl-venlafaxine succinat salz
EP1266659A1 (en) * 2001-06-11 2002-12-18 Pantarhei Bioscience B.V. Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
TW200301101A (en) * 2001-12-05 2003-07-01 Wyeth Corp Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
CA2574310A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions

Also Published As

Publication number Publication date
WO2006012476A2 (en) 2006-02-02
AU2005266996A1 (en) 2006-02-02
US20060019966A1 (en) 2006-01-26
CA2574315A1 (en) 2006-02-02
IL180732A0 (en) 2007-07-04
MX2007000848A (es) 2007-03-26
BRPI0513711A (pt) 2008-05-13
KR20070045278A (ko) 2007-05-02
RU2007102290A (ru) 2008-08-27
JP2008507551A (ja) 2008-03-13
US20120065240A1 (en) 2012-03-15
EP1773321A2 (en) 2007-04-18
WO2006012476A3 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
NO20070914L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
NL301145I2 (nl) Tirbanibulin
SE0203713D0 (sv) Novel compounds
TW200407305A (en) Novel compounds
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
SE0203752D0 (sv) New compounds
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
SE0502254L (sv) Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
NO20074332L (no) Fremgangsmate og preparat for behandling av sentralnervesystemforstyrrelser
NO20070124L (no) Nye disubstituerte fenylpiperidiner/piperaziner som modulatorer av dopamin neurotransmisjon
HRP20080262T3 (en) 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
NO20070912L (no) Fremgangsmate for behandling av nervesystemforstyrrelser og tilstander
DE602004016316D1 (de) 4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer
DE60317935D1 (de) Alpha-aminoamid-derivate als mittel gegen migräne
ATE457309T1 (de) Modulatoren von peripheren 5-ht-rezeptoren
WO2004052858A3 (en) Inhibitors of monoamine uptake
NO20070915L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
NO20071466L (no) 3-substituerte-5- og 6-aminoalkyl indol-2-karboksylsyreamider og relaterte analoger som inhibitorer av kaseinkinase IE
MXPA05010678A (es) Derivados de 4-(2-fenilsulfanil-fenil)-1,2,3,6-tetrahidropiridina como inhibidores de recaptacion de serotonina.
GEP20104888B (en) Use of carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application